The White House has withdrawn the nomination of Dr. Heidi Overton to lead the Food and Drug Administration (FDA) due to insufficient support from Senate Republicans. Overton, a physician and White House domestic policy advisor, faced significant questions from senators regarding her willingness to diverge from former President Donald Trump's positions, particularly on vaccine-related issues.

Senator Bill Cassidy, the Republican chairman of the Senate health committee, indicated he remained undecided on Overton's nomination ahead of a scheduled Wednesday vote. Cassidy had previously expressed concerns about Overton's support for Trump's proposal to separate combination vaccines, such as the measles, mumps, and rubella (MMR) shot, calling it "almost disqualifying." He also questioned her scientific independence and ability to challenge Trump and Health Secretary Robert F. Kennedy Jr.

Confirmation required the backing of all 12 Republicans on the Senate Health, Education, Labor and Pensions Committee, which holds 11 Democratic seats. Without the committee's approval, Overton's chances of a full Senate vote were slim. Republicans had been seeking to confirm nominees before the transfer of power to Senate Democrats in January.

Overton's nomination also drew opposition from within the "Make America Healthy Again" movement. Calley Means, a figure within this movement, alleged that White House aides, including Overton, worked to advance policies at the behest of industry lobbyists and were "antagonistic to what people voted for."

The White House has previously withdrawn other health nominations. Dr. David Weldon, Trump's initial nominee for the Centers for Disease Control and Prevention (CDC), was replaced due to uncertain Republican backing. Similarly, two of Trump's surgeon general nominees were withdrawn after facing Republican pushback.

The FDA is currently led on an acting basis by Kyle Diamantas, an attorney and associate of Donald Trump Jr., who previously served as the agency's top food official. The FDA under former Commissioner Dr. Marty Makary experienced scientific disputes, leadership changes, and reports of low staff morale and internal dysfunction, with the agency losing approximately 20% of its employees since Trump took office.